Matches in SemOpenAlex for { <https://semopenalex.org/work/W2037051159> ?p ?o ?g. }
- W2037051159 endingPage "34" @default.
- W2037051159 startingPage "27" @default.
- W2037051159 abstract "Objective This retrospective study assessed varicose vein treatment patterns and associated thrombotic complications in a real-world setting. Methods A retrospective study was conducted with health care claims data from Truven Health, covering more than 40 million insured lives per year and representing all U.S. census regions. The study sample included subjects aged ≥18 years with a new diagnosis of varicose veins who had received at least one invasive treatment (eg, surgery, endovenous thermal ablation [radiofrequency or laser], or sclerotherapy [liquid or foam]). The adverse events of interest included a coded diagnosis of deep venous thrombosis (DVT) or pulmonary embolism within 30 days of a claim for invasive treatment. Patients treated between January 1, 2008, and June 30, 2012, were observed for up to 2 years after diagnosis. Results There were 985,632 unique subjects diagnosed with varicose veins; of them, a total of 131,887 subjects met all of the study criteria: 63,033 (47.8%) having multiple therapies; 22,980 (17.4%) having laser ablation; 21,637 (16.4%) having radiofrequency ablation; 12,708 (9.6%) having sclerotherapy; and 11,529 (8.7%) having surgery. The mean age of the sample was 52.8 years, ranging from 51.5 years (surgery cohort) to 54.5 years (radiofrequency ablation cohort); 77% of the sample was female, ranging from 71% (radiofrequency ablation cohort) to 92% (sclerotherapy cohort). The mean time to treatment after diagnosis was 105 days, ranging from 75 days (sclerotherapy cohort) to 116 days (radiofrequency ablation cohort). The diagnosed prevalence (percentage of subjects within each treatment cohort) of DVT was as follows: radiofrequency ablation, 4.4%; multiple therapies—same day, 3.4%; laser ablation, 3.1%; multiple therapies—deferred, 2.6%; surgery, 2.4%; and sclerotherapy, 0.8%. For pulmonary embolism, the diagnosed prevalence was as follows: radiofrequency ablation, surgery, and laser ablation, 0.3% each; and multiple therapies—same day, multiple therapies—deferred, and sclerotherapy, 0.2% each. Conclusions Thrombotic complications associated with invasive varicose vein treatments in the real-world setting may be higher than what has been reported in clinical trials, particularly in regard to DVT after endovenous thermal ablation therapy. A better understanding of these patterns of adverse events may have an impact on new strategies to safely and effectively manage patients with varicose veins. This retrospective study assessed varicose vein treatment patterns and associated thrombotic complications in a real-world setting. A retrospective study was conducted with health care claims data from Truven Health, covering more than 40 million insured lives per year and representing all U.S. census regions. The study sample included subjects aged ≥18 years with a new diagnosis of varicose veins who had received at least one invasive treatment (eg, surgery, endovenous thermal ablation [radiofrequency or laser], or sclerotherapy [liquid or foam]). The adverse events of interest included a coded diagnosis of deep venous thrombosis (DVT) or pulmonary embolism within 30 days of a claim for invasive treatment. Patients treated between January 1, 2008, and June 30, 2012, were observed for up to 2 years after diagnosis. There were 985,632 unique subjects diagnosed with varicose veins; of them, a total of 131,887 subjects met all of the study criteria: 63,033 (47.8%) having multiple therapies; 22,980 (17.4%) having laser ablation; 21,637 (16.4%) having radiofrequency ablation; 12,708 (9.6%) having sclerotherapy; and 11,529 (8.7%) having surgery. The mean age of the sample was 52.8 years, ranging from 51.5 years (surgery cohort) to 54.5 years (radiofrequency ablation cohort); 77% of the sample was female, ranging from 71% (radiofrequency ablation cohort) to 92% (sclerotherapy cohort). The mean time to treatment after diagnosis was 105 days, ranging from 75 days (sclerotherapy cohort) to 116 days (radiofrequency ablation cohort). The diagnosed prevalence (percentage of subjects within each treatment cohort) of DVT was as follows: radiofrequency ablation, 4.4%; multiple therapies—same day, 3.4%; laser ablation, 3.1%; multiple therapies—deferred, 2.6%; surgery, 2.4%; and sclerotherapy, 0.8%. For pulmonary embolism, the diagnosed prevalence was as follows: radiofrequency ablation, surgery, and laser ablation, 0.3% each; and multiple therapies—same day, multiple therapies—deferred, and sclerotherapy, 0.2% each. Thrombotic complications associated with invasive varicose vein treatments in the real-world setting may be higher than what has been reported in clinical trials, particularly in regard to DVT after endovenous thermal ablation therapy. A better understanding of these patterns of adverse events may have an impact on new strategies to safely and effectively manage patients with varicose veins." @default.
- W2037051159 created "2016-06-24" @default.
- W2037051159 creator A5007664303 @default.
- W2037051159 creator A5007968325 @default.
- W2037051159 creator A5024057961 @default.
- W2037051159 creator A5066102500 @default.
- W2037051159 creator A5079081966 @default.
- W2037051159 date "2015-01-01" @default.
- W2037051159 modified "2023-10-16" @default.
- W2037051159 title "Assessment of thrombotic adverse events and treatment patterns associated with varicose vein treatment" @default.
- W2037051159 cites W1892390879 @default.
- W2037051159 cites W1968866389 @default.
- W2037051159 cites W1987063247 @default.
- W2037051159 cites W1989215478 @default.
- W2037051159 cites W1990087845 @default.
- W2037051159 cites W1995036178 @default.
- W2037051159 cites W1997772280 @default.
- W2037051159 cites W2013010190 @default.
- W2037051159 cites W2017488845 @default.
- W2037051159 cites W2028227321 @default.
- W2037051159 cites W2036062897 @default.
- W2037051159 cites W2039979165 @default.
- W2037051159 cites W2071687686 @default.
- W2037051159 cites W2099262802 @default.
- W2037051159 cites W2099404042 @default.
- W2037051159 cites W2106199499 @default.
- W2037051159 cites W2107244661 @default.
- W2037051159 cites W2111987503 @default.
- W2037051159 cites W2112418729 @default.
- W2037051159 cites W2136139586 @default.
- W2037051159 cites W2136868651 @default.
- W2037051159 cites W2137881942 @default.
- W2037051159 cites W2144965330 @default.
- W2037051159 cites W2163325440 @default.
- W2037051159 cites W2170110656 @default.
- W2037051159 doi "https://doi.org/10.1016/j.jvsv.2014.09.007" @default.
- W2037051159 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26993677" @default.
- W2037051159 hasPublicationYear "2015" @default.
- W2037051159 type Work @default.
- W2037051159 sameAs 2037051159 @default.
- W2037051159 citedByCount "27" @default.
- W2037051159 countsByYear W20370511592015 @default.
- W2037051159 countsByYear W20370511592016 @default.
- W2037051159 countsByYear W20370511592017 @default.
- W2037051159 countsByYear W20370511592018 @default.
- W2037051159 countsByYear W20370511592019 @default.
- W2037051159 countsByYear W20370511592020 @default.
- W2037051159 countsByYear W20370511592021 @default.
- W2037051159 countsByYear W20370511592022 @default.
- W2037051159 countsByYear W20370511592023 @default.
- W2037051159 crossrefType "journal-article" @default.
- W2037051159 hasAuthorship W2037051159A5007664303 @default.
- W2037051159 hasAuthorship W2037051159A5007968325 @default.
- W2037051159 hasAuthorship W2037051159A5024057961 @default.
- W2037051159 hasAuthorship W2037051159A5066102500 @default.
- W2037051159 hasAuthorship W2037051159A5079081966 @default.
- W2037051159 hasConcept C126322002 @default.
- W2037051159 hasConcept C141071460 @default.
- W2037051159 hasConcept C167135981 @default.
- W2037051159 hasConcept C197934379 @default.
- W2037051159 hasConcept C201903717 @default.
- W2037051159 hasConcept C2776265017 @default.
- W2037051159 hasConcept C2777377203 @default.
- W2037051159 hasConcept C2777475103 @default.
- W2037051159 hasConcept C2778230777 @default.
- W2037051159 hasConcept C2778902805 @default.
- W2037051159 hasConcept C2778959117 @default.
- W2037051159 hasConcept C2779480337 @default.
- W2037051159 hasConcept C2780868729 @default.
- W2037051159 hasConcept C71924100 @default.
- W2037051159 hasConcept C72563966 @default.
- W2037051159 hasConceptScore W2037051159C126322002 @default.
- W2037051159 hasConceptScore W2037051159C141071460 @default.
- W2037051159 hasConceptScore W2037051159C167135981 @default.
- W2037051159 hasConceptScore W2037051159C197934379 @default.
- W2037051159 hasConceptScore W2037051159C201903717 @default.
- W2037051159 hasConceptScore W2037051159C2776265017 @default.
- W2037051159 hasConceptScore W2037051159C2777377203 @default.
- W2037051159 hasConceptScore W2037051159C2777475103 @default.
- W2037051159 hasConceptScore W2037051159C2778230777 @default.
- W2037051159 hasConceptScore W2037051159C2778902805 @default.
- W2037051159 hasConceptScore W2037051159C2778959117 @default.
- W2037051159 hasConceptScore W2037051159C2779480337 @default.
- W2037051159 hasConceptScore W2037051159C2780868729 @default.
- W2037051159 hasConceptScore W2037051159C71924100 @default.
- W2037051159 hasConceptScore W2037051159C72563966 @default.
- W2037051159 hasIssue "1" @default.
- W2037051159 hasLocation W20370511591 @default.
- W2037051159 hasLocation W20370511592 @default.
- W2037051159 hasOpenAccess W2037051159 @default.
- W2037051159 hasPrimaryLocation W20370511591 @default.
- W2037051159 hasRelatedWork W2037051159 @default.
- W2037051159 hasRelatedWork W2116853871 @default.
- W2037051159 hasRelatedWork W2137272592 @default.
- W2037051159 hasRelatedWork W2216065911 @default.
- W2037051159 hasRelatedWork W2317073603 @default.
- W2037051159 hasRelatedWork W2345209605 @default.
- W2037051159 hasRelatedWork W2491735079 @default.